A recent study reveals that oral Janus kinase (JAK) inhibitors significantly improve hair regrowth in individuals with alopecia areata. Published in the American Journal of Clinical Dermatology, the research found that patients had nearly 8 times higher odds of achieving near-complete scalp hair regrowth compared to those on a placebo. The study, a systematic review and meta-analysis, searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through November 2025, identifying 12 randomized controlled trials that met the criteria, all registered in advance with PROSPERO.
Alopecia areata, an autoimmune disorder causing hair loss, affects approximately 2% of people at some point in their lives, with onset most common before age 40. It generates an estimated 2.4 million U.S. outpatient visits annually. Before 2022, treatment options were limited, often relying on off-label immunosuppressants. The introduction of JAK inhibitors has offered new hope, but until now, data comparing these drugs directly has been lacking. The study excluded topical JAK inhibitors, non-randomized studies, and subgroup-only analyses, focusing on oral treatments for patients aged 12 and older.
Study Design and Findings
Researchers analyzed 12 randomized controlled trials involving 4,141 participants aged 12 and older. The trials included various JAK inhibitors such as baricitinib, ritlecitinib, brepocitinib, deuruxolitinib, ivarmacitinib, and tofacitinib. One trial compared tofacitinib against azathioprine, while the remaining 11 included a placebo arm. The pooled population comprised 2,558 women and 1,583 men, with a mean age of 35.8 years. Participants had a mean baseline Severity of Alopecia Tool (SALT) score of 86.0 and a mean episode duration of 4.8 years. The pooled data showed that by week 24, patients on JAK inhibitors had a 7.99 times higher odds of achieving a SALT score of 20 or less, indicating 80% or more scalp coverage, compared to placebo.
By week 36, the odds increased to 9.40 times higher for achieving a SALT score of 10 or less compared to placebo. Despite moderate heterogeneity across trials, with I² values reaching up to 67%, the results consistently favored JAK inhibitors over placebo. Adverse events were slightly more common with JAK inhibitors, with an odds ratio of 1.60, but serious adverse events did not differ significantly from placebo, with an odds ratio of 1.04. The risk of discontinuing treatment due to adverse events was also not significantly different, with an odds ratio of 1.22.
Safety and Limitations
The study noted that while JAK inhibitors showed a favorable safety profile, six of the 12 trials raised concerns due to missing data and selective reporting. The researchers described these trials as having “some concerns” on their risk-of-bias assessment. Estimates for serious and severe adverse events were unstable due to the low occurrence of such events in individual trials. Evidence for adolescents remains particularly limited, with only one trial including this age group, and adolescents comprising just 15% of that trial’s population. The researchers emphasized the need for head-to-head trials and longer-term safety data to better compare these drugs.
For clinicians, the pooled data provides valuable insights into the efficacy of JAK inhibitors. However, the lack of direct comparisons between these drugs means that treatment decisions will likely continue to rely on individual trial results and cost considerations. The researchers called for longer pharmacovigilance data to clarify how different oral JAK inhibitors compare, not just with placebo but with each other.
Implications for Treatment
The findings show the potential of JAK inhibitors as a transformative treatment for alopecia areata, a condition that affects millions worldwide. While these drugs significantly improve hair regrowth, the absence of comparative data between different inhibitors leaves room for further research. For payers, the lack of head-to-head data means coverage decisions will likely continue to be based on individual trial results and pricing rather than evidence of one agent’s superiority. This study marks a significant step forward in understanding the role of JAK inhibitors in managing alopecia areata, offering hope to patients with limited treatment options.